David J. Nutt

Imperial College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (7)

Per Carlbring

Adjunct Professor in e-Health

University of Southern Denmark

DENMARK

View details

David Erritzoe

Imperial College London

UNITED KINGDOM

View details

Alan K. Davis

Johns Hopkins University

UNITED STATES

View details

Robin Carhart-Harris

University of Oxford

UNITED KINGDOM

View details

Simon B. Goldberg

Assistant Professor

University of Wisconsin-Madison

UNITED STATES

View details

Hannah Thurgur

Imperial College London

UNITED KINGDOM

View details

Leon Fonville

Imperial College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David J. Nutt

Research Interests

Explore related searches

Contact this professor

Articles (20)

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study

How to put psychiatrists back at the centre of medicine’s innovation

Medicinal Cannabis Use Among People with Obsessive Compulsive Disorder: Changes in Quality of Life After Three Months

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT)

Authors' response to letter ‘On the use of open‐label studies for the evaluation of cannabis‐based products for the treatment of long‐COVID’

Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21

Feasibility of a cannabidiol‐dominant cannabis‐based medicinal product for the treatment of long COVID symptoms: A single‐arm open‐label feasibility trial

Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: a systematic review and individual participant data meta-analysis

Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications

Pharmacological Dissection of Antipsychotics

Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins

Imidazoline-I2 PET Tracers in Neuroimaging

Receptor-informed network control theory links LSD and psilocybin to a flattening of the brain’s control energy landscape

Functional Alternatives to Alcohol

Increased global integration in the brain after psilocybin therapy for depression

Alcohol and the Brain

Putting the MD back into MDMA

Collaborators (7)

Per Carlbring

David Erritzoe

Alan K. Davis

Robin Carhart-Harris

Simon B. Goldberg

Hannah Thurgur

Leon Fonville

Make your next move.